Dr Nicolas Dennis Vlachakis, MD | |
2378 Tanoble Dr, Altadena, CA 91001-2730 | |
(626) 794-8874 | |
(626) 794-8874 |
Full Name | Dr Nicolas Dennis Vlachakis |
---|---|
Gender | Male |
Speciality | Podiatrist - Public Medicine |
Location | 2378 Tanoble Dr, Altadena, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1790050896 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
213EP0504X | Podiatrist - Public Medicine | CFE37623 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Nicolas Dennis Vlachakis, MD 2378 Tanoble Dr, Altadena, CA 91001-2730 Ph: (626) 794-8874 | Dr Nicolas Dennis Vlachakis, MD 2378 Tanoble Dr, Altadena, CA 91001-2730 Ph: (626) 794-8874 |
News Archive
Survival rates for breast cancer in older women could be significantly improved by a simple awareness programme that promotes early presentation of the disease, according to results of the first trial of its kind presented at the National Cancer Research Institute Conference in Birmingham today (Sunday).
Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy.
BioAmber, Inc. has been awarded a 2011 Presidential Green Chemistry Challenge Award, presented by the Environmental Protection Agency (EPA) and the American Chemical Society (ACS). The Award promotes technology that provides substantial environmental benefits using green chemistry. BioAmber's platform was recognized as the leading technology in the field of succinic acid.
Human Genome Sciences, Inc. today announced the closing of its public offering of 17,825,000 newly issued shares of its common stock at a price to the public of $26.75 per share, which includes 2,325,000 shares sold upon exercise by the underwriters of their option to purchase additional shares. The net proceeds to the Company from the offering are approximately $456.3 million, after deducting the underwriting discount and estimated offering expenses.
› Verified 4 days ago